The sealed bottles were supposed to contain 30 Montelukast sodium tablets, but instead contained 90 Losartan potassium tablets. Montelukast is used to control allergy and asthma symptoms, whereas Losartan is used to control high blood pressure.
The tablet mix-up could cause renal dysfunction, elevated potassium level and low blood pressure.
“This risk is especially high for pregnant women taking the allergy and asthma medication Montelukast because Losartan, which is indicated to treat high blood pressure, could harm or kill the fetus,” the FDA warned.
The affected lot number is MON17384, which has an expiration date of Dec. 31, 2019.
More articles on pharmacy:
Blood pressure drug recalled after labeling mix-up
Narcan maker to be acquired by Emergent Biosolutions for $735M
US-Mexico trade deal grants drugmakers 10 years of patent exclusivity on biologics
